AbbVie's Telisotuzumab Adizutecan Granted Two FDA Breakthrough Designations

The U.S. Food and Drug Administration (FDA) has awarded two Breakthrough Therapy Designations to AbbVie's telisotuzumab adizutecan (Temab-A; ABBV-400). These designations are for its use in refractory, metastatic colorectal cancer when combined with bevacizumab, and for non-small cell lung cancer. This status aims to accelerate the development and review process for drugs treating serious or life-threatening conditions.